Prospective PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Distant recurrence free survival
研究概览
简要总结
There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF
详细描述
The main objective of this study is to determine whether patients with SCLC who have a metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor rest by PET CT and biopsy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histopathologic confirmation
- •Limited disease
排除标准
- •Other histology than small cell lung cancer
- •Further tumor diagnosis
- •ECOG 3 or worse
- •Extensive disease
结局指标
主要结局
Distant recurrence free survival
时间窗: 2 months to 5 years
Distant recurrence free survival
Overall survival
时间窗: 2 months to 5 years
Overall survival
Local recurrence free survival
时间窗: 2 months to 5 years
Local recurrence free survival
次要结局
未报告次要终点
研究者
Maja Guberina
PD Dr. med. (MD) Maja Guberina, specialist in radiation oncology, senior consultant
University Hospital, Essen